News

AbstractAcute chest syndrome (ACS) is a common pulmonary complication in children with sickle cell disease, defined by a new pulmonary infiltrate on imaging…

Our mission is to train the next generation of providers with expertise in the care of individuals with sickle cell disease (SCD) throughout their lifespan.…

Agios Pharmaceuticals will present Phase 3 trial results for mitapivat in sickle cell disease at EHA 2026.Quiver AI SummaryAgios Pharmaceuticals announced that…

Newer oral anticoagulants, or blood thinners, were linked to a lower risk of clinically relevant nonmajor bleeding than warfarin, an older blood thinner, in adults…

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through…

Key TakeawaysAgios aligned with FDA on a 52-week, randomized, double-blind confirmatory trial (n≈159; age ≥12 years) using transfusion-free status from weeks 4–52…

ABSTRACTErythrocytaphoresis or RBC exchange (RBCX) is a key intervention in the management of sickle cell anemia for both chronic prophylaxis and emergent clinical…

As insecurity intensifies across the country, Joseph Ifechukwu Agbanyin, a 25-year-old software engineering graduate living with sickle cell anemia, has called on…

Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by chronic hemolytic anemia, recurrent vaso-occlusive crises, progressive organ damage, and…

April 2026 brought major developments in hematology, particularly in sickle cell disease (SCD), with advances spanning phase 3 therapeutics, gene-editing strategies…